Lebrikizumab shows good long-term efficacy and reasonable safety in patients with moderate to severe atopic dermatitis according to the 52-week results from the phase 3 ADvocate1 and ADvocate2 trials.
The first pediatric trial of baricitinib for childhood eczema suggests that symptoms improve, and the safety profile is similar to that seen in adults.
Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, was approved September 9 by the FDA for treating adults with moderate to severe plaque psoriasis.
Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasisNew analysis to be presented at the 2022 European Academy of Dermatology and Venereology Cong.
The authors of the study see their findings as an early but promising step in finding better models to improve cardiovascular outcomes for patients with psoriatic disease.